Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Preimplantation genetic testing using Karyomapping for a paternally inherited reciprocal translocation: a case study.

Beyer CE, Lewis A, Willats E, Mullen J.

J Assist Reprod Genet. 2019 May;36(5):951-963. doi: 10.1007/s10815-019-01413-0. Epub 2019 Feb 12.

PMID:
30756205
2.

Defining the limits of detection for chromosome rearrangements in the preimplantation embryo using next generation sequencing.

Cuman C, Beyer CE, Brodie D, Fullston T, Lin JI, Willats E, Zander-Fox D, Mullen J.

Hum Reprod. 2018 Jul 10. doi: 10.1093/humrep/dey227. [Epub ahead of print]

PMID:
30007310
3.

Natural selection between day 3 and day 5/6 PGD embryos in couples with reciprocal or Robertsonian translocations.

Beyer CE, Willats E.

J Assist Reprod Genet. 2017 Nov;34(11):1483-1492. doi: 10.1007/s10815-017-1009-0. Epub 2017 Jul 29.

4.

Supersensitive fluorescent semen analysis: validation on azoospermic and oligozoospermic samples.

Beyer CE, Kayler B, Osborne E, McLachlan R, Osianlis T.

Fertil Steril. 2012 Oct;98(4):843-8.e1. doi: 10.1016/j.fertnstert.2012.06.036. Epub 2012 Jul 18.

PMID:
22818286
5.

Preimplantation genetic diagnosis for chromosome rearrangements - one blastomere biopsy versus two blastomere biopsy.

Brodie D, Beyer CE, Osborne E, Kralevski V, Rasi S, Osianlis T.

J Assist Reprod Genet. 2012 Aug;29(8):821-7. doi: 10.1007/s10815-012-9782-2. Epub 2012 May 12.

6.

TRPV1 Antagonists and Chronic Pain: Beyond Thermal Perception.

Brandt MR, Beyer CE, Stahl SM.

Pharmaceuticals (Basel). 2012 Feb 2;5(2):114-32. doi: 10.3390/ph5020114.

7.

Involvement of noradrenergic neurotransmission in the stress- but not cocaine-induced reinstatement of extinguished cocaine-induced conditioned place preference in mice: role for β-2 adrenergic receptors.

Mantsch JR, Weyer A, Vranjkovic O, Beyer CE, Baker DA, Caretta H.

Neuropsychopharmacology. 2010 Oct;35(11):2165-78. doi: 10.1038/npp.2010.86. Epub 2010 Jul 7.

8.

WAY-318068: a novel, potent and selective noradrenaline re-uptake inhibitor with activity in rodent models of pain and depression.

Whiteside GT, Dwyer JM, Harrison JE, Beyer CE, Cummons T, Manzino L, Mark L, Johnston GH, Strassle BW, Adedoyin A, Lu P, Piesla MJ, Pulicicchio CM, Erve JC, Platt BJ, Hughes ZA, Rogers KE, Deecher DC, Trybulski EJ, Kennedy JD, Zhang P, Leventhal L.

Br J Pharmacol. 2010 Jul;160(5):1105-18. doi: 10.1111/j.1476-5381.2010.00690.x.

9.

Depression-like phenotype following chronic CB1 receptor antagonism.

Beyer CE, Dwyer JM, Piesla MJ, Platt BJ, Shen R, Rahman Z, Chan K, Manners MT, Samad TA, Kennedy JD, Bingham B, Whiteside GT.

Neurobiol Dis. 2010 Aug;39(2):148-55. doi: 10.1016/j.nbd.2010.03.020. Epub 2010 Apr 8.

PMID:
20381618
10.

Angiotensin IV elevates oxytocin levels in the rat amygdala and produces anxiolytic-like activity through subsequent oxytocin receptor activation.

Beyer CE, Dwyer JM, Platt BJ, Neal S, Luo B, Ling HP, Lin Q, Mark RJ, Rosenzweig-Lipson S, Schechter LE.

Psychopharmacology (Berl). 2010 May;209(4):303-11. doi: 10.1007/s00213-010-1791-1. Epub 2010 Mar 12.

PMID:
20224888
11.

Preclinical characterization of BRL 44408: antidepressant- and analgesic-like activity through selective alpha2A-adrenoceptor antagonism.

Dwyer JM, Platt BJ, Rizzo SJ, Pulicicchio CM, Wantuch C, Zhang MY, Cummons T, Leventhal L, Bender CN, Zhang J, Kowal D, Lu S, Rajarao SJ, Smith DL, Shilling AD, Wang J, Butera J, Resnick L, Rosenzweig-Lipson S, Schechter LE, Beyer CE.

Int J Neuropsychopharmacol. 2010 Oct;13(9):1193-205. doi: 10.1017/S1461145709991088. Epub 2010 Jan 5.

PMID:
20047711
12.

Metabolite identification in rat brain microdialysates by direct infusion nanoelectrospray ionization after desalting on a ZipTip and LTQ/Orbitrap mass spectrometry.

Erve JC, Beyer CE, Manzino L, Talaat RE.

Rapid Commun Mass Spectrom. 2009 Dec;23(24):4003-12. doi: 10.1002/rcm.4341.

PMID:
19918933
13.

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.

Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, Rotella D, Feenstra RW, Kruse C, Broqua P, Beyer CE, McCreary AC, Pausch MH, Marquis KL.

J Pharmacol Exp Ther. 2010 Jan;332(1):190-201. doi: 10.1124/jpet.109.157388. Epub 2009 Oct 14.

PMID:
19828876
14.

Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists.

Zhou D, Stack GP, Lo J, Failli AA, Evrard DA, Harrison BL, Hatzenbuhler NT, Tran M, Croce S, Yi S, Golembieski J, Hornby GA, Lai M, Lin Q, Schechter LE, Smith DL, Shilling AD, Huselton C, Mitchell P, Beyer CE, Andree TH.

J Med Chem. 2009 Aug 13;52(15):4955-9. doi: 10.1021/jm900374r.

PMID:
19719241
15.

Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist.

Ring RH, Schechter LE, Leonard SK, Dwyer JM, Platt BJ, Graf R, Grauer S, Pulicicchio C, Resnick L, Rahman Z, Sukoff Rizzo SJ, Luo B, Beyer CE, Logue SF, Marquis KL, Hughes ZA, Rosenzweig-Lipson S.

Neuropharmacology. 2010 Jan;58(1):69-77. doi: 10.1016/j.neuropharm.2009.07.016. Epub 2009 Jul 15.

PMID:
19615387
16.

Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists.

Bernotas RC, Lenicek S, Antane S, Cole DC, Harrison BL, Robichaud AJ, Zhang GM, Smith D, Platt B, Lin Q, Li P, Coupet J, Rosenzweig-Lipson S, Beyer CE, Schechter LE.

Bioorg Med Chem. 2009 Jul 15;17(14):5153-63. doi: 10.1016/j.bmc.2009.05.055. Epub 2009 May 29.

PMID:
19523834
17.

Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant.

Beyer CE, Lin Q, Platt B, Malberg J, Hornby G, Sullivan KM, Smith DL, Lock T, Mitchell PJ, Hatzenbuhler NT, Evrard DA, Harrison BL, Magolda R, Pangalos MN, Schechter LE, Rosenzweig-Lipson S, Andree TH.

Br J Pharmacol. 2009 May;157(2):307-19. doi: 10.1111/j.1476-5381.2009.00146.x. Epub 2009 Mar 26.

18.

The supra-additive hyperactivity caused by an amphetamine-chlordiazepoxide mixture exhibits an inverted-U dose response: negative implications for the use of a model in screening for mood stabilizers.

Kelly MP, Logue SF, Dwyer JM, Beyer CE, Majchrowski H, Cai Z, Liu Z, Adedoyin A, Rosenzweig-Lipson S, Comery TA.

Pharmacol Biochem Behav. 2009 Jun;92(4):649-54. doi: 10.1016/j.pbb.2009.03.003. Epub 2009 Mar 18.

PMID:
19303035
19.

Preimplantation genetic screening outcomes are associated with culture conditions.

Beyer CE, Osianlis T, Boekel K, Osborne E, Rombauts L, Catt J, Kralevski V, Aali BS, Gras L.

Hum Reprod. 2009 May;24(5):1212-20. doi: 10.1093/humrep/den502. Epub 2009 Jan 30.

PMID:
19181741
20.

Acid sensing ion channel (ASIC) inhibitors exhibit anxiolytic-like activity in preclinical pharmacological models.

Dwyer JM, Rizzo SJ, Neal SJ, Lin Q, Jow F, Arias RL, Rosenzweig-Lipson S, Dunlop J, Beyer CE.

Psychopharmacology (Berl). 2009 Mar;203(1):41-52. doi: 10.1007/s00213-008-1373-7. Epub 2008 Oct 24.

PMID:
18949460
21.

ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.

Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, Smith D, Olsen M, Kouranova E, Lai M, Pruthi F, Pulicicchio C, Day M, Gilbert A, Pausch MH, Brandon NJ, Beyer CE, Comery TA, Logue S, Rosenzweig-Lipson S, Marquis KL.

J Pharmacol Exp Ther. 2008 Dec;327(3):827-39. doi: 10.1124/jpet.108.136580. Epub 2008 Aug 27.

PMID:
18753411
22.

Schedule-induced polydipsia: a rat model of obsessive-compulsive disorder.

Platt B, Beyer CE, Schechter LE, Rosenzweig-Lipson S.

Curr Protoc Neurosci. 2008 Apr;Chapter 9:Unit 9.27. doi: 10.1002/0471142301.ns0927s43.

PMID:
18428677
23.

Inhibition of uptake 2 (or extraneuronal monoamine transporter) by normetanephrine potentiates the neurochemical effects of venlafaxine.

Rahman Z, Ring RH, Young K, Platt B, Lin Q, Schechter LE, Rosenzweig-Lipson S, Beyer CE.

Brain Res. 2008 Apr 8;1203:68-78. doi: 10.1016/j.brainres.2008.01.062. Epub 2008 Feb 5.

PMID:
18321472
24.

Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders.

Leonard SK, Dwyer JM, Sukoff Rizzo SJ, Platt B, Logue SF, Neal SJ, Malberg JE, Beyer CE, Schechter LE, Rosenzweig-Lipson S, Ring RH.

Psychopharmacology (Berl). 2008 May;197(4):601-11. doi: 10.1007/s00213-008-1080-4. Epub 2008 Mar 3.

PMID:
18311561
25.

Do selective serotonin reuptake inhibitors acutely increase frontal cortex levels of serotonin?

Beyer CE, Cremers TI.

Eur J Pharmacol. 2008 Feb 12;580(3):350-4. doi: 10.1016/j.ejphar.2007.11.028. Epub 2007 Nov 24.

PMID:
18177637
26.

Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.

Cole DC, Stock JR, Lennox WJ, Bernotas RC, Ellingboe JW, Boikess S, Coupet J, Smith DL, Leung L, Zhang GM, Feng X, Kelly MF, Galante R, Huang P, Dawson LA, Marquis K, Rosenzweig-Lipson S, Beyer CE, Schechter LE.

J Med Chem. 2007 Nov 15;50(23):5535-8. Epub 2007 Oct 19.

PMID:
17948978
27.

Innovations in CNS drug discovery: differentiating strategies to treat depression.

Beyer CE, Hughes ZA.

Expert Opin Drug Discov. 2007 Oct;2(10):1369-77. doi: 10.1517/17460441.2.10.1369.

PMID:
23484532
28.

Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon.

Rajarao SJ, Platt B, Sukoff SJ, Lin Q, Bender CN, Nieuwenhuijsen BW, Ring RH, Schechter LE, Rosenzweig-Lipson S, Beyer CE.

Neuropeptides. 2007 Oct;41(5):307-20. Epub 2007 Jul 16.

PMID:
17637475
29.

Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466.

Schechter LE, Lin Q, Smith DL, Zhang G, Shan Q, Platt B, Brandt MR, Dawson LA, Cole D, Bernotas R, Robichaud A, Rosenzweig-Lipson S, Beyer CE.

Neuropsychopharmacology. 2008 May;33(6):1323-35. Epub 2007 Jul 11.

30.

Development of a liquid chromatography/tandem mass spectrometry method for the quantitation of acetylcholine and related neurotransmitters in brain microdialysis samples.

Zhang MY, Hughes ZA, Kerns EH, Lin Q, Beyer CE.

J Pharm Biomed Anal. 2007 Jun 28;44(2):586-93. Epub 2007 Feb 23.

PMID:
17383138
31.

Differentiating antidepressants of the future: efficacy and safety.

Rosenzweig-Lipson S, Beyer CE, Hughes ZA, Khawaja X, Rajarao SJ, Malberg JE, Rahman Z, Ring RH, Schechter LE.

Pharmacol Ther. 2007 Jan;113(1):134-53. Epub 2006 Sep 27. Review.

PMID:
17010443
32.

Synthesis and biological evaluation of novel compounds within a class of 3-aminochroman derivatives with dual 5-HT1A receptor and serotonin transporter affinity.

Hatzenbuhler NT, Evrard DA, Harrison BL, Huryn D, Inghrim J, Kraml C, Mattes JF, Mewshaw RE, Zhou D, Hornby G, Lin Q, Smith DL, Sullivan KM, Schechter LE, Beyer CE, Andree TH.

J Med Chem. 2006 Jul 27;49(15):4785-9.

PMID:
16854086
33.

Neurochemical changes in the RVM associated with peripheral inflammatory pain stimuli.

Smith VA, Beyer CE, Brandt MR.

Brain Res. 2006 Jun 20;1095(1):65-72. Epub 2006 May 30.

PMID:
16730668
34.

Alpha 2A-adrenoceptors enhance the serotonergic effects of fluoxetine.

Beyer CE, Lin Q, Rosenzweig-Lipson S, Schechter LE.

Eur J Pharmacol. 2006 Jun 13;539(3):164-7. Epub 2006 Apr 19.

PMID:
16714015
35.

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.

Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH.

J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4.

PMID:
16675639
36.

Innovative approaches for the development of antidepressant drugs: current and future strategies.

Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, Rosenzweig-Lipson S.

NeuroRx. 2005 Oct;2(4):590-611. Review.

37.

Measurement of neurotransmitters from extracellular fluid in brain by in vivo microdialysis and chromatography-mass spectrometry.

Zhang MY, Beyer CE.

J Pharm Biomed Anal. 2006 Feb 24;40(3):492-9. Epub 2005 Aug 26. Review.

PMID:
16125893
38.
39.

Regulators of G-protein signaling 4: modulation of 5-HT1A-mediated neurotransmitter release in vivo.

Beyer CE, Ghavami A, Lin Q, Sung A, Rhodes KJ, Dawson LA, Schechter LE, Young KH.

Brain Res. 2004 Oct 1;1022(1-2):214-20.

PMID:
15353231
40.

Studying rat brain neurochemistry using nanoprobe NMR spectroscopy: a metabonomics approach.

Khandelwal P, Beyer CE, Lin Q, Schechter LE, Bach AC 2nd.

Anal Chem. 2004 Jul 15;76(14):4123-7.

PMID:
15253652
41.

Nanoprobe NMR spectroscopy and in vivo microdialysis: new analytical methods to study brain neurochemistry.

Khandelwal P, Beyer CE, Lin Q, McGonigle P, Schechter LE, Bach AC 2nd.

J Neurosci Methods. 2004 Feb 15;133(1-2):181-9.

PMID:
14757359
42.
43.

Cocaine sensitization: modulation by dopamine D2 receptors.

Beyer CE, Steketee JD.

Cereb Cortex. 2002 May;12(5):526-35.

PMID:
11950770
44.
45.

Repeated exposure to inhaled toluene induces behavioral and neurochemical cross-sensitization to cocaine in rats.

Beyer CE, Stafford D, LeSage MG, Glowa JR, Steketee JD.

Psychopharmacology (Berl). 2001 Mar 1;154(2):198-204.

PMID:
11314682
46.
47.
48.

Sexual coercion content in 21 sexuality education curricula.

Beyer CE, Ogletree RJ.

J Sch Health. 1998 Nov;68(9):370-5.

PMID:
9854693
49.

The GABAB agonist baclofen modifies cocaine self-administration in rats.

Shoaib M, Swanner LS, Beyer CE, Goldberg SR, Schindler CW.

Behav Pharmacol. 1998 May;9(3):195-206.

PMID:
9832934
50.

Antioxidant properties of melatonin--an emerging mystery.

Beyer CE, Steketee JD, Saphier D.

Biochem Pharmacol. 1998 Nov 15;56(10):1265-72. Review. Erratum in: Biochem Pharmacol 1999 May 1;57(9):1077.

PMID:
9825724

Supplemental Content

Loading ...
Support Center